

Pre-vaccination carriage prevalence of *Streptococcus pneumoniae* serotypes among internally displaced people in Somaliland

Authors:

Kevin van Zandvoort^{1*}, Abdirahman Ibrahim Hassan², Mohamed Bobe³, Casey L. Pell⁴, Mohammed Saed Ahmed³, Belinda D. Ortika⁴, Saed Ibrahim³, Mohamed Ismail Abdi³, Mustapha A Karim², Rosalind M Eggo¹, Sulieman Yusuf², Jason Hinds^{5, 6}, Saed Mohamood Soleman², Rachael Cummings⁷, Catherine McGowan^{1,7}, Kim Mulholland^{1,4}, Mohamed Abdi Hergeeye², Catherine Satzke^{4,8,9}, Francesco Checchi¹, Stefan Flasche¹

* Corresponding author: Kevin.Van-Zandvoort@lshtm.ac.uk

1. Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine. United Kingdom.
2. Republic of Somaliland Ministry of Health Development. Somaliland.
3. Save the Children International Somaliland. Somaliland.
4. Infection, Immunity and Global Health, Murdoch Children's Research Institute, Melbourne, Australia.
5. Institute for Infection and Immunity, St. George's, University of London, United Kingdom
6. BUGS Bioscience, London Bioscience Innovation Centre, London, United Kingdom
7. Save the Children UK. United Kingdom.
8. Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia
9. Department of Paediatrics, The University of Melbourne, Melbourne, Australia

Abstract

Populations affected by humanitarian crises likely experience high burdens of pneumococcal disease. *Streptococcus pneumoniae* carriage estimates are essential to understand pneumococcal transmission dynamics and the potential impact of pneumococcal conjugate vaccines (PCV). Over 100 million people are forcibly displaced worldwide, yet here we present only the second pneumococcal carriage estimates for a displaced population.

In October 2019, we conducted a cross-sectional survey among internally displaced people (IDP) living in Digaale, a permanent IDP camp in Somaliland where PCV has not been implemented. We collected nasopharyngeal swab samples from 453 residents which were assessed for presence of pneumococci and serotyped using DNA microarray.

We found that pneumococcal carriage prevalence was 36% (95%CI 31 – 40) in all ages, and 70% (95%CI 64 – 76) in children under 5. The three most common serotypes were vaccine serotypes 6B, 19F, and 23. We estimated that the serotypes included in the 10-valent PNEUMOSIL vaccine were carried by 41% (95%CI 33 – 49) of all pneumococcal carriers and extrapolated that they caused 52% (95%CI 35 – 72) of invasive pneumococcal disease. We found some evidence that pneumococcal carriage was associated with recent respiratory symptoms, the total number of physical contacts made, and with malnutrition in children under 5. Through linking with a nested contact survey we projected that pneumococcal exposure of children under 2 was predominantly due to contact with children aged 2-5 (39%; 95%CI 32 – 48) and 6-14 (25%; 95%CI 18 – 33).

These findings suggest considerable potential for direct and indirect protection against pneumococcal disease in Digaale through PCV use in children and potentially adolescents.

1 Introduction

2 The United Nations High Commissioner for Refugees estimates that over 100 million people
3 were forcibly displaced worldwide in 2022, of whom over half are internally displaced and
4 more than 40% are children (1). These people typically live in overcrowded settings, have
5 poor access to hygiene and healthcare, and thus experience high morbidity and mortality
6 from respiratory diseases (2–4) including invasive disease from *Streptococcus pneumoniae*
7 (pneumococcus) (5). There is a lack of health research in these populations in general (6),
8 and for pneumococcal disease specifically (2,4). Pneumococcal prevalence estimates are
9 only available for one other displaced population globally, living in Mae La refugee camp,
10 Thailand (7).

11 Pneumococcal Conjugate Vaccines (PCV) are highly efficacious and have been used
12 routinely for protecting children against pneumococcal colonization and disease in most
13 countries worldwide. Five PCVs are currently used for childhood immunization: Prevenar 20
14 (20 valent, targeting 20 of the over 100 serotypes), Vaxneuvance (15 valent), Prevenar 13
15 (13 valent), Synflorix and PNEUMOSIL (both 10 valent) (8–10). However, despite the high
16 prevalence of risk factors for severe disease and intense transmission, they are rarely
17 offered to populations that have become displaced as a result of food insecurity, conflict,
18 natural disasters, or other emergencies (2).

19 Pneumococcal colonization is common and is a precursor to disease, thus providing an
20 opportunity to assess the likely risk for disease, even in small populations, without costly
21 disease surveillance programmes that would be difficult to establish in displaced populations
22 (11). Such information is crucial to inform the design of effective pneumococcal
23 immunization strategies in displaced populations where routine immunization is rarely
24 possible (2).

- 25 We conducted a cross-sectional survey to estimate nasopharyngeal carriage prevalence and
26 related risk factors in Digaale, a camp for internally displaced people (IDPs) in Somaliland
27 (2). PCVs had not yet been introduced in Somaliland at the time of writing.

28 **Methods**

29 *Study population and sampling method*

30 We conducted a cross-sectional survey in October-November 2019. The Digaale IDP camp
31 was established in 2014 and, at the time of our study, housed an estimated population of
32 3,000 people largely displaced due to drought and food insecurity during 2013 and 2014
33 (12). The camp is located about 4km south-east of Hargeisa, the capital of Somaliland, and
34 consists of corrugated-steel shelters. The population is served by a school and primary
35 health centre.

36 We visited all 894 shelters in Digaale and invited households to participate in our survey. We
37 first administered a structured household survey among consenting households to establish
38 their composition and collect household-level information on shelter conditions,
39 pneumococcal risk factors, and retrospective mortality and demographic changes. We then
40 selected and invited individual household members for participation in a survey on carriage,
41 contact and individual-level risk factors. We aimed to sample 100 individuals in each of the
42 following age groups: <1, 1, 2-5, 6-14, 15-29, 30-49, and ≥ 50 years (y) old to detect age-
43 specific pneumococcal prevalence within 10% precision. We purposively oversampled young
44 children who have the highest incidence of pneumococcal carriage and disease. Quota
45 sampling by age was used to select individual household members.

46 We returned to individual participants two days after the household survey and study
47 enrolment to conduct the contact and risk factor survey, in which we asked about individual-
48 level risk factors including social contacts, and measured anthropometry for children aged 6-
49 59 months. Further details about the design and sampling method, as well as detailed social
50 contact and household-level findings, are described in Van Zandvoort et al (12). In the final
51 week of data collection, one to four weeks after participation in the contact survey, we
52 followed up participants to collect a nasopharyngeal swab sample. To compensate for loss-

53 to-follow up, additional participants were sampled from household members of participating
54 households.

55 All swabs were collected at a community hall in the centre of the camp. During swab
56 collection, we asked participants whether they had experienced any respiratory symptoms
57 (cough, sore throat, sneezing, wheezing, headache, or fever) or used any antibiotics in the
58 two weeks prior. Responses for children under 10y were provided by an adult parent or
59 caregiver. Participants with a contraindication for a nasopharyngeal swab such as facial
60 trauma were excluded.

61

62 *Sample collection, storage, and shipment*

63 Trained nurses collected nasopharyngeal swabs from each participant using flexible
64 paediatric- (Ultra Minitip) or adult-size (Flexible Minitip) flocked swabs (FLOQSwabs; Copan
65 Diagnostics, USA), following WHO recommendations (13,14). Paediatric-sized swabs were
66 used for children under 15y. The nasopharyngeal swabs were stored in screw-capped tubes
67 containing 1 ml of skim milk-tryptone-glucose-glycerol (STGG) medium and kept on wet ice
68 in cool boxes immediately after collection. Samples were transferred to a -20°C freezer at
69 the Ministry of Health Development national cold chain facility within eight hours of collection
70 (15). Within two weeks after collection, all samples were transferred to an ultra-low
71 temperature (ULT) freezer at the culture laboratory of the Somaliland National Tuberculosis
72 Hospital. Due to technical issues with the ULT freezer, samples were temporarily stored at -
73 20°C for 15 days in March 2020.

74 We used a prequalified shipping solution with phase change materials (PCMs) that provided
75 passive cooling to keep contents below -15°C for up to 96h as per manufacturer
76 specifications (Schaumplast, DE) (16). We found that it maintained temperatures below -
77 15°C up to 160h in an empty trial shipment from London to Hargeisa when conditioned at
78 ULT (Supplemental Material Section B). Samples were first shipped to Nairobi, Kenya,

79 where they were repackaged and placed on dry ice for further transport to the Murdoch
80 Children's Research Institute (MCRI) in Melbourne, Australia. We successfully completed a
81 pilot shipment of 81 samples in May 2021, and shipped all remaining samples in December
82 2021. Transit delays during the second shipment extended the period during which only
83 passive cooling was provided by PCMs to 11 days. There was no temperature monitoring
84 during this second shipment, but we project that temperatures may have increased to $>0^{\circ}\text{C}$
85 for up to 2.5 days based on temperature measurements from the pilot shipment. We
86 explored any difference in carriage estimates between the two shipments in a sensitivity
87 analysis.

88

89 *Microbiological analysis*

90 Upon arrival at the MCRI laboratory, STGG swab samples were immediately stored at ULT
91 until testing. Briefly, samples were thawed, vortexed, and DNA extracted from 100 μl using
92 the QIAcube HT machine (Qiagen) following a protocol described previously (17).
93 Concurrently, each sample was cultured overnight on selective agar, and growth harvested if
94 alpha-haemolytic colonies were present (18). Real-time quantitative PCR, targeting the *lytA*
95 gene (*lytA* qPCR) (19), was conducted as previously described, except for using 5 μl
96 template DNA and the AriaMX PCR system (Agilent) (18). For samples with presumptive
97 pneumococci (*lytA* qPCR cycle threshold <40 and alpha-haemolytic growth), DNA was
98 extracted from harvested colonies using the QIAcube HT machine (Qiagen) and the
99 resultant DNA serotyped using microarray (Senti-SP version 1.5, BUGS Bioscience) (18).
100 Pneumococcal density was calculated using a genomic DNA standard curve (18). Serotype-
101 specific density was calculated by multiplying the pneumococcal density (as determined by
102 *lytA* qPCR) by the relative abundance of the serotype (as determined by microarray).
103 Carriage density estimates were \log_{10} -transformed and reported as \log_{10} genome
104 equivalents/ml (GE/ml).

105 *Statistical analysis*

106 Serotypes were grouped as non-encapsulated (NESp), vaccine serotypes (VT) for each of
107 PNEUMOSIL, Synflorix, Prevenar 13, Vaxneuvence, and Prevenar 20 vaccines, or non-
108 vaccine serotypes (NVT). Unless stated otherwise, we used PNEUMOSIL targeted
109 serotypes to define VT in our base case analysis, because PNEUMOSIL was specifically
110 developed to provide a lower cost alternative that targets the main serotypes causing
111 pneumococcal disease in low and middle income countries (20). Analyses that defined VT
112 using the other vaccines are presented in the Supplementary Material.

113 We estimated the population and age-specific prevalence of pneumococcal serotypes with
114 95% binomial confidence intervals. To account for multiple serotype carriage, serotypes
115 were weighted by their relative abundance within a sample to calculate the serotype
116 distribution including co-carried serotypes, so that the weights of all serotypes in a sample
117 summed to one. Unweighted distributions of all and dominant-only serotypes were assessed
118 in a sensitivity analysis. We define serotypes ranked with the highest relative abundance in a
119 single sample as dominant serotypes, and used logistic regression to assess the odds that
120 serotypes were dominant.

121 As we sampled a large proportion of households (65%) and individuals (17%) living in
122 Digaale, we used finite population corrections (FPC) to calculate standard errors used in
123 population-level estimates. To correct for imbalance resulting from quota sampling and thus
124 improve the representativeness, we applied poststratification weights based on age group
125 and gender (12,21). We assessed the sensitivity of our population level estimates to
126 poststratification in additional analyses. We used the *Survey* package in *R* to perform
127 poststratification weighting and to apply the FPC when estimating weighted means,
128 proportions, and quantiles where applicable (22).

129 To project the proportion of current IPD cases caused by serotypes covered by PCVs, we
130 combined the dataset with age- and serotype-specific estimates of invasiveness by Løchen

131 et al (23), and computed confidence intervals by bootstrapping our dataset and invasiveness
132 estimates. More details are provided in the Supplemental Material.

133 To estimate the likely contribution of different age groups to pneumococcal exposure and
134 transmission, we followed a method developed by Qian et al (24) and calculated the
135 proportion of colonisations attributable to contact with different age groups by linking the
136 estimates of carriage prevalence with previously reported contact patterns (12) in those
137 individuals and the likelihood of colonisation among those contacts. As the contact and
138 carriage datasets featured different statistical error processes, we computed confidence
139 intervals for this analysis through bootstrapping from each parameter's uncertainty
140 distribution.

141 We used logistic regression to test the univariate association of likely risk factors with the
142 odds of pneumococcal carriage and used linear regression to test their association with
143 mean logged overall carriage density in pneumococcal carriers. Age and gender were
144 included as *a priori* defined confounding variables in both analyses, but no other multivariate
145 analyses were conducted due to data sparsity. We also used logistic regression to test for
146 any association between the odds of multiple carriage and age. FPC and poststratification
147 weights were not applied in regression analyses.

148 All analyses were conducted in R4.2.2. Analysis scripts and anonymised aggregated data
149 will be made available on final publication.

150


151 *Ethical approval*

152 Ethical approval for the study was granted by the Research Ethical Committee of the London
153 School of Hygiene and Tropical Medicine (16577) and the Republic of Somaliland Ministry of
154 Health Development (2/13075/2019). The funding sources had no role in the study design;
155 collection, analysis, and interpretation of data; or in writing the report.

156 Results

157 Participant sampling and enrolment

158 We enrolled 464 (65%) households and collected demographic data from 2,049 individuals
159 living in these households. A contact and individual-level risk-factor survey was conducted
160 among 509 participants. We collected a nasopharyngeal swab from 365 of these
161 participants. An additional 88 nasopharyngeal swabs were collected from other individuals
162 from consenting households. In total, 453 swabs were collected (Figure 1).



163

164 FIGURE 1. FLOWCHART OF SAMPLING PROCEDURE.

165 All households that were present were invited to participate in the survey. A structured household
166 survey was conducted in consenting households. Individual household members were selected using
167 quota sampling and invited for a contact and individual-level risk factor survey. Participants were
168 followed up after one to four weeks to administer a nasopharyngeal swab. Additional household
169 members were sampled from consenting households using quota sampling to compensate for loss to
170 follow-up.

171 *Sample characteristics*

172 Two (0.4%) nasopharyngeal swab samples were excluded due to insufficient sample volume
 173 for laboratory testing. An additional two (0.4%) samples were *lytA* positive, indicating
 174 pneumococcal colonization, but with no growth prohibiting microarray serotyping; these were
 175 included only in non-serotype specific carriage prevalence analyses. Due to data entry
 176 errors, 53 swabs (12%) could not be fully linked to records in contact or household datasets.
 177 This included 16 swabs that could not be linked to their household information, and 6
 178 samples without information on age and gender (Supplemental Material Section A). Data
 179 from these swabs are excluded in analyses that require linking to those data, but included
 180 otherwise.

181 67% of the study participants from whom swabs were collected were female (Table 1).
 182 Median age was 13y and median household size was 5 people. Pneumococci were detected
 183 in 39% (175/445) of samples, with at least one PNEUMOSIL VT present in 49% (85/175) of
 184 positive samples. We estimated the overall carriage prevalence in Digaale as 36% (95%CI
 185 31 – 40%), with 41% (95%CI 33 – 49%) of carriers carrying at least one VT. Estimated
 186 prevalence was 70% (95%CI 64 – 76%) in children under 5y, with VTs carried by 61%
 187 (95%CI 53 – 69) of carriers. Large proportions of participants reported respiratory symptoms
 188 (64%) and antibiotic use (36%) in the two weeks leading up to the sampling.

TABLE 1. SAMPLE CHARACTERISTICS, CARRIAGE PREVALENCE, AND INVASIVE DISEASE LIKELY CAUSED BY VACCINE SEROTYPES

Variable	Obs ^a	Sample value	Population est ^b	Population est (<5y) ^b		
<i>Sample characteristics (unweighted)</i>						
Median age (y)	447	13 (IQR 3 – 40)	.	.		
Percentage female	298/447	66.7%	.	.		
Median household size (people)	433	5 (IQR 3 – 6)	.	.		
Median household members <5y (people)	433	0 (IQR 0 – 2)	.	.		
<i>Potential risk factors</i>						
Respiratory symptoms	261/410	63.7%	61.1%	55.9 – 66.2	73.5%	67.0 – 79.9
Antibiotic use	148/409	36.2%	31.6%	27.0 – 36.3	45.9%	38.6 – 53.2
Direct contacts	365	9.5	9.6	9.1 – 10.0	9.9%	9.4 – 10.3

TABLE 1. SAMPLE CHARACTERISTICS, CARRIAGE PREVALENCE, AND INVASIVE DISEASE LIKELY CAUSED BY VACCINE SEROTYPES


Variable	Obs ^a	Sample value	Population est ^b	Population est (<5y) ^b
<i>Carriage prevalence</i>				
Pneumococcal carriage	175/445 ^c	39.3%	35.8%	70.0%
Non-encapsulated carriage	18/175	10.3%	14.9%	6.6%
<i>Proportion of carriers with VT</i>				
PNEUMOSIL ^d	85/175	48.6%	40.8%	60.9%
Synflorix ^e	84/175	48.0%	40.0%	59.7%
Prevenar 13 ^f	98/175	56.0%	51.0%	62.9%
Vaxneuvance ^g	98/175	56.0%	51.0%	62.9%
Prevenar 20 ^h	110/175	62.9%	58.0%	68.3%
<i>Projected proportion of IPD covered by PCVsⁱ</i>				
PNEUMOSIL ^d	.	53.3%	51.9%	68.1%
Synflorix ^e	.	61.3%	60.8%	74.2%
Prevenar 13 ^f	.	72.7%	75.1%	78.0%
Vaxneuvance ^g	.	73.2%	75.8%	79.0%
Prevenar 20 ^h	.	81.0%	81.6%	87.5%

- Total number of observations in the dataset. For proportions, both numerators and denominators are shown.
- Mean value and corresponding 95%CI. Post-stratification weights and finite population corrections have been used to calculate population estimates.
- Six observations excluded due to missing age or gender data prohibiting post-stratification weighting.
- Serotypes 1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F, and 23F.
- Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
- Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.
- Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F.
- Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F.
- Estimated from serotype-specific invasiveness estimates. See Supplemental Material Section D for more details.

189

190 *Serotype distribution*

191 The three most prevalent pneumococcal serotypes overall (6B, 19F, and 23F) were VTs
192 included in all PCVs, followed by three serotypes (6C, 11A, 16F) of which 11A is only
193 included in Prevenar 20, and all others are NVTs (Figure 2). A similar serotype distribution
194 was observed in children under 5y, while 15B/C, 6B, and 6C were the most prevalent
195 serotypes in people over 5y (Supplemental Figure C2). There was little difference in the
196 serotype distribution when restricting analysis to dominant serotypes alone, or without
197 weighting for relative abundance in multiple serotype carriers (Supplemental Figure C1). We
198 extrapolate that 52% (95%CI 35 – 71) of all IPD cases and 68% (95%CI 50 – 82) of IPD
199 cases in <5y were caused by VT serotypes, with slightly increased proportions for higher
200 valency vaccines (Table 1).



201
202
203
204
205
206

FIGURE 2. PNEUMOCOCCAL SEROTYPE DISTRIBUTION.

Bars show the carriage prevalence of pneumococcal serotypes identified in Digaale IDP camp, weighted by their relative abundance. Coloured bars show the serotypes included in the five PCVs, dark grey bars non-encapsulated pneumococci, and light grey bars other serotypes not included in the PCVs. Error bars show 95% confidence intervals for each estimate.

207

208 *Multiple serotype carriage*

209 Co-colonization with more than one serotype was detected in 30% (52/175) of samples with
210 pneumococci, corresponding to a population-level prevalence of 39% (95%CI 35 – 44%).

211 There were 36 samples in which two serotypes were detected, 16 samples with three
212 serotypes, and three samples with more than three serotypes. The odds that the serotype
213 was dominant was 2.0 (95%CI 1.1 – 3.7) times higher for VTs than for NVTs in all carriers,
214 and 2.8 (95%CI 1.0 – 8.0) times higher among carriers colonized with both VT and NVT
215 (Supplemental Table C2).

216 *Sensitivity analyses*

217 We found no evidence of a difference in pneumococcal carriage, density of pneumococcal
218 serotypes, number of carried serotypes, or serotype distribution between our two sample
219 shipments (Supplemental Material Section B). Post stratifying our estimates did not
220 substantially affect pneumococcal carriage prevalence estimates (Supplemental Table C5).

221


222 *Antimicrobial resistance*

223 Microarray assays detected the presence of select antimicrobial resistance genes in 30%
224 (95%CI 21 – 41%) of samples (Supplemental Table C2). In those samples, the most
225 common detected genes typically associated with antimicrobial resistance were *tetM* (28%
226 [95%CI 19 – 39]) and *ermB* (9% [95%CI 4 – 16]). We restricted this analysis to samples in
227 which no other species and only a single pneumococcal serotype were detected

228

229 *Carriage prevalence and serotype distribution by age*

230 Overall carriage prevalence was 79% (95%CI 72 – 87%) and 67% (95%CI 58 – 75%) in
231 children under 2 and 2-5y, respectively. Carriage prevalence was 41% (95%CI 30 – 51%) in
232 children aged 6-14y, 28% (95%CI 16 – 41%) in people aged 15-29y, 18% (95%CI 7 – 28%) in
233 adults aged 30-49y and 8% (95%CI 4 – 12) in adults aged ≥ 50 y (Figure 3). Co-colonization
234 rates decreased by age alongside reductions in overall prevalence, although this reduction
235 was not statistically significant. The proportion of VT among all carriers was similar across age
236 groups and robust to the definition of VT for different PCV products (Supplemental Figure C3).



237


238 **FIGURE 3. PREVALENCE AND SEROTYPE DISTRIBUTION BY AGE.**

239 Bars show the estimated prevalence of pneumococcal serotypes by age group, weighted for age and
 240 gender. Error bars show 95% confidence intervals around overall pneumococcal carriage prevalence.
 241 Colours show the prevalence of serotypes that are carried; VT: only vaccine type(s), NVT: only non-
 242 vaccine type(s); NT: only non-encapsulated type(s); VT + NVT: both vaccine- and non-vaccine
 243 type(s). Multiple carriage with non-encapsulated type(s) is shown as a darker shading.

244

245 *Contribution of different age groups to pneumococcal exposure*

246 We projected that a large proportion (39% [95%CI 32 – 48]) of pneumococcal exposure of
 247 children <2y may be attributed to contact with 2-5y children, followed by school age children
 248 aged 6-14y (25% [95%CI 18 – 33]) (Figure 4 and Supplemental Table C6). A similar
 249 contribution was made by carriers of these age groups to exposure of children aged 2-5y
 250 (45% [95%CI 38 – 53]; and 30% [95%CI 22 – 38]). Most of the exposure of school age
 251 children, however, was found to be attributable to other school age children (51% [95%CI 42
 252 – 60]), followed by 2-5y olds (26% [95%CI 20 – 32]). While carriage prevalence was high in
 253 children <2y, this age group was found to contribute relatively little to onward transmission to
 254 any age group.



255

256 **FIGURE 4. THE CONTRIBUTION OF DIFFERENT AGE GROUPS TOWARDS THE AGE-SPECIFIC**
257 **EXPOSURE TO PNEUMOCOCCUS.**

258 Bars show the average proportion of contacts made by a contactor of age i (x-axis), with
259 pneumococci-carrying contactees of different age groups. Shades of green stratify into age group of
260 the contactee, i.e. the person potentially transmitting to the contactor.

261

262 *Association of risk factors with pneumococcal carriage and carriage density*

263 We found no evidence that the number of overall household members increased the odds of
264 pneumococcal carriage, but weak evidence that living with one additional household
265 member <5y of age increased the odds of carriage by 1.3 (95%CI 1.0 – 1.8) (Table 2). The
266 odds of carriage were 2.0 (95%CI 1.2 – 3.3) times higher in people with recent respiratory
267 symptoms. Having a cough (2.0 [95%CI 1.2 – 3.3]) had the strongest association, followed
268 by having a sore throat (1.7 [95%CI 1.0 – 3.0]). There was some evidence that the odds of
269 carriage increased by 1.1 (95%CI 1.0 – 1.2) for every additional physical contact reported.
270 We found good evidence for a reduction in the odds of carriage for improved scores of
271 weight-for-age (0.6 [95%CI 0.4 – 0.9]) and height-for-age (0.6 [95%CI 0.4 – 0.8]) among
272 children 6-59 months old, but no evidence for an association with weight-for-height or
273 middle-upper arm circumference. Notably, we did not find any evidence of an association
274 with self-reported antibiotic use.

TABLE 2. ASSOCIATION BETWEEN RISK FACTORS AND PNEUMOCOCCAL CARRIAGE

Variable	OR^a	95%CI	p-value	N^b
<i>Demographic characteristics</i>				
Household size	1.05	0.95 – 1.17	0.336	431
Household members <5y	1.32	0.99 – 1.76	0.054	431
<i>Shelter quality</i>				
House leakage	1.15	0.69 – 1.95	0.591	431
House draught	0.68	0.41 – 1.13	0.140	431
<i>Indoor air pollution</i>				
Use firewood as fuel	1.03	0.55 – 1.92	0.938	434
Use charcoal as fuel	0.75	0.46 – 1.19	0.223	434
Ventilation				431
yes	0.49	0.20 – 1.16		
cook outside	0.56	0.25 – 1.24	0.348	
<i>Current health^c</i>				
Antibiotic use	1.28	0.78 – 2.10	0.324	407
Respiratory symptoms	1.99	1.20 – 3.32	0.008	408
Cough	2.00	1.23 – 3.25	0.005	408
Sore throat	1.69	0.95 – 3.00	0.072	408
Headache	0.74	0.41 – 1.32	0.309	408
Fever	1.17	0.70 – 1.94	0.545	408
Diarrhoea	1.62	0.73 – 3.73	0.244	408
<i>Morbidities^d</i>				
Pneumonia 6m ^e	1.28	0.68 – 2.41	0.451	363
Sickle Cell	1.25	0.38 – 3.77	0.697	363
Asthma	0.96	0.11 – 5.73	0.968	363
Diabetes	1.09	0.05 – 8.57	0.939	363
<i>Individual substance use</i>				
Tobacco	0.50	0.03 – 2.92	0.524	363
Khat	0.63	0.03 – 3.93	0.681	363
<i>Household substance use^f</i>				
Smoking	1.42	0.84 – 2.39	0.186	434
Snuff	1.64	0.66 – 4.17	0.287	434
Khat	1.31	0.81 – 2.12	0.265	434
<i>Contact behaviour</i>				
Total number of direct contacts	1.04	0.97 – 1.12	0.278	362
Total number of physical contacts	1.08	1.01 – 1.15	0.034	362
<i>Malnutrition in <5y olds</i>				
Weight-for-age z-score	0.59	0.37 – 0.90	0.018	112
Weight-for-height z-score	1.16	0.79 – 1.70	0.440	112
Height-for-age z-score	0.61	0.43 – 0.82	0.003	112
MUAC ^g (in cm)	0.80	0.53 – 1.21	0.229	112

TABLE 2. ASSOCIATION BETWEEN RISK FACTORS AND PNEUMOCOCCAL CARRIAGE

Variable	OR ^a	95%CI	p-value	N ^b
a.	Estimates are adjusted for age and gender.			
b.	Total number of records used in regression.			
c.	Self-reported antibiotic use and symptoms in 2 weeks preceding the survey.			
d.	Self-reported diagnosed morbidities.			
e.	Pneumonia diagnosis in the 6m preceding the survey.			
f.	Substance use by at least one household member.			
g.	Middle-Upper-Arm-Circumference			

275

276 We also tested the association between these risk factors and the density of pneumococcal
277 carriage (Supplemental Table C3) and found weak evidence that living with one additional
278 household member <5y was associated with a small 0.2 (95%CI -0.0 – 0.4) increase in mean
279 log₁₀ GE/ml, while associations with respiratory symptoms were either non-significant or
280 negative: the mean log₁₀ density was 0.40 (95%CI -0.8 – 0.0) lower in participants reporting
281 a sore throat in the two weeks preceding the survey. Again, we did not find any significant
282 association with self-reported antibiotic use. There was very weak evidence for an increase
283 in children’s mean log₁₀ density with a one-unit increase in weight-for-height z-score (0.2
284 [95%CI -0.0 – 0.4]).

285 Discussion

286 This is the first study to have estimated pneumococcal serotype prevalence in Somaliland
287 and in an IDP camp. We find high carriage prevalence of 36% in all age groups, and 70% in
288 children under 5y. Between 40 and 58% of pneumococcal carriers carried serotypes
289 included in PCVs, depending on the PCV product, and the three most prevalent serotypes
290 were covered by all PCVs. The majority of exposure to pneumococcal carriers in children
291 younger than 15y may have been attributable to carriers aged 2-5y and 6-14y, with little
292 exposure from carriers aged younger than two years of age. We found that pneumococcal
293 carriage was associated with the number of household members aged <5y, a recent cough,
294 the total number of physical contacts in all age groups, and with stunting in children aged
295 <5y. We estimate that all PCVs cover a substantial proportion of serotypes likely causing
296 IPD in this population.

297 While we did not find local evidence of a significant association for all, many risk factors
298 previously found to be associated with pneumococcal carriage are present in this population
299 (25). Residents in Digaale live in overcrowded conditions and likely experience high levels of
300 indoor air pollution. On average, one in five children are malnourished, and residents report
301 a high frequency of direct contacts involving physical touch (12,26,27). While carriage
302 prevalence was high, it is similar to that observed in non-displaced populations in other high-
303 transmission settings in east Africa, and not as high as prevalence observed in rural Gambia
304 where high carriage prevalence is sustained into older adulthood (28–31). Despite a high
305 disease burden, displaced populations are understudied, and we are only aware of one
306 other published carriage survey conducted in Mae La, a long-term camp for displaced
307 people in Thailand, where carriage prevalence was estimated at a similar 80% in children
308 <2y (7).

309 The most prevalent serotypes in Digaale (6B, 19F, and 23F) have often been observed to
310 dominate carriage in other PCV-naïve populations, although the relatively high prevalence of
311 6C and low prevalence of 6A and 19A in our study is unusual (28–30,32). Around 50% of

312 serotypes we detected were VTs, and the prevalence of observed serotypes included in the
313 10-valent Synflorix and PNEUMOSIL PCVs were similar. The proportion of VTs increased
314 with valency of the vaccine. However, due to our relatively small sample size, serotype-
315 specific confidence intervals are very wide. We estimate that any of the five PCVs are likely
316 to cover the serotypes causing the majority of the pneumococcal disease burden. While
317 serotype replacement would mitigate the overall PCV impact, substantial reductions in
318 pneumococcal disease have been observed where PCVs have been introduced with
319 sufficient coverage (33,34). While we did not collect data on the pneumococcal disease
320 burden in Digaale, 43% of children under two years of age were reported to have been
321 diagnosed with pneumonia in the six months preceding the survey (12), and pneumococci
322 were one of the leading causes of childhood pneumonia globally in the pre-PCV era (35).

323 The combined contact and prevalence estimates showed that pneumococcal transmission in
324 the <2y in Digaale was mostly driven by children aged 2-5y (39%) and 6-14y (25%), with
325 little contribution to transmission from children younger than 2y old who have fewer social
326 contacts. This could be important when designing vaccine strategies, especially those that
327 partially rely on controlling pneumococcal transmission by indirect effects or need to prolong
328 campaign effects in settings where continued vaccination through routine EPI schedule is
329 not possible, as this requires extending the age range of the eligible population (2). While
330 Digaale is an established camp that is safe and easy to access, this is not the case for many
331 other displaced populations. In conflict settings, it is often not feasible to introduce routine
332 immunization, and policy makers may choose alternative strategies that aim to immunize the
333 subgroups that drive transmission, thereby indirectly protecting other subgroups at highest
334 risk of severe disease.

335 Participants reported high rates of antibiotic usage in the two weeks preceding sample
336 collection. This may be associated with the high proportion of participants with respiratory
337 symptoms in the same period. However, we cannot rule out reporting bias. We found no
338 association of antibiotic use with reduced carriage contrary to findings in other settings

339 (29,36,37). Although in this study we do not have estimates of phenotypic pneumococcal
340 resistance, microarray testing identified genes typically associated with pneumococcal
341 resistance in a third of all samples, which may be consistent with high antibiotic pressure.
342 The *tetM* gene, known to encode tetracycline resistance, was identified in 28% of
343 pneumococci, mirroring its high prevalence in other studies (38,39). The *ermB* gene was
344 found in 9% of pneumococci, and is associated with macrolide resistance (40). Future
345 improved understanding of antimicrobial resistance in pneumococci would be useful to better
346 understand the impact of more clinically-relevant antibiotics for standard care as well as the
347 potential impact of mass-drug administration campaigns, a potential alternative intervention
348 to reduce the pneumococcal disease burden proposed for crisis settings (41).

349 We assessed the relationship between a number of known risk factors with the odds of
350 pneumococcal carriage and the mean pneumococcal carriage density. We found
351 relationships in the expected direction for some risk-factors, such as an increased odds of
352 carriage for participants with a higher number of household members under 5y of age, those
353 with more direct contacts, and those with recent respiratory symptoms. Asymptomatic
354 pneumococcal carriage has previously been found to be associated with rhinitis, and may be
355 affected by other respiratory infections (42). It should be noted that confidence intervals were
356 very wide due to a relatively low sample size and low variability within many risk factors.
357 Moreover, we only adjusted our estimates for age and gender, and they are likely affected by
358 residual confounding, while the large number of significance tests means that some spurious
359 associations may have been estimated.

360 There are several limitations to our study. The study population was substantially smaller
361 than expected as many shelters were uninhabited at the time of the study. Thus, we only
362 reached 65% of our target sample size of 700 participants, particularly in young children,
363 where we only reached 24% and 43% of our target sample size of 100 each in children aged
364 <1 and 1y (12). We therefore pooled the <1 and 1y age groups in a single <2y age group,
365 which allowed us to estimate age-specific prevalence with sufficient precision, but a larger

366 sample would have resulted in more detailed estimates. We could only conduct data
367 collection during daylight hours and may have missed older individuals who work outside
368 Digaale, as many leave the camp very early in the morning and return late at night. This is
369 likely reflected in the gender distribution of the recruited sample, but unlikely to have affected
370 our carriage estimates, as prevalence is low in these older age groups and unlikely to differ
371 substantially from those who were present in Digaale. We post-stratified our estimates to
372 adjust for any imbalances in our sample and did not detect differences. Although,
373 pneumococcal carriage is generally consistent across seasons (43), we only conducted a
374 single cross-sectional survey and do not know how estimates may change throughout the
375 year. Carriage prevalence was similar to that in general populations in East Africa, but no
376 other prevalence estimates exist for Somaliland, and we cannot infer how results may differ
377 from the general Somaliland population. Our study was not powered to detect relationships
378 between carriage and risk factors, which may explain why we did not find statistically
379 significant effects in most univariate analyses, and a prospective cohort design would be
380 more suitable to infer causality. Finally, many risk factors were self-reported, and their
381 accuracy may be affected by reporting bias.

382 Ideally, pneumococci are stored at ULT to maintain long-time viability, but we experienced
383 several challenges related to sample storage and shipment. Sample shipment was
384 substantially delayed, partly due to the COVID-19 pandemic, and after several months of
385 storage at ULT, swabs had to be temporarily transferred to a -20°C freezer to allow for ULT
386 freezer repairs. We were not able to transport samples at ULT as local airlines did not accept
387 shipments of dry ice. However, we have shown separately that effect on pneumococcal
388 viability is limited if stored at -20°C for up to three weeks (15), which was maintained in our
389 study in the periods that ULT storage was not feasible. We further monitored sample viability
390 by incorporation of *lytA* qPCR, a molecular screening assay that is not expected to be
391 affected by culture viability, and did not observe a large number of non-culturable samples
392 that were *lytA* positive. Despite transit delays during the second shipment of most of our

393 samples during which temperatures may have exceeded 20°C for up to 2.5 days, we found
394 no difference between carriage and VT prevalence estimates between these samples and
395 those transported during the first shipment. Hence, we believe any effect on sample viability
396 was limited and did not greatly affected our results, supported by the ability to culture at high
397 prevalence and with detection of serotypes carried at low abundance.

398 **Conclusion**

399 We found high pneumococcal carriage prevalence in a PCV-naïve population living in an
400 IDP camp in Somaliland, consistent with carriage rates in non-displaced populations in other
401 high transmission settings. About half of all circulating pneumococci were included in
402 currently available PCVs. We estimate that at least half of all resulting IPD cases in this
403 population were caused by serotypes included in PCVs, indicating the potential for
404 substantial vaccine effects. Transmission was primarily driven by children 2-5 years and 6-
405 14 years old, partially exceeding the proposed age eligibility for PCV campaigns that aim to
406 temporarily reduce transmission in crisis-affected populations. These findings advance our
407 understanding of pneumococcal carriage in crisis-affected populations and provide important
408 evidence for the design of future vaccination strategies.

Sources of Funding

This work was supported by Elrha's Research for Health in Humanitarian Crises (R2HC) Programme, which aims to improve health outcomes by strengthening the evidence base for public health interventions in humanitarian crises. The R2HC programme is funded by the UK Government (DFID), the Wellcome Trust, and the UK National Institute for Health Research (NIHR). SF acknowledges a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (grant: 208812/Z/17/Z). In addition, RME acknowledges an NIHR (grant: NIHR200908) for the Health Protection Research Unit in Modelling and Economics at LSHTM. MCRI was supported by the Victorian Government's Operational Infrastructure Support Program. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care.

Acknowledgements

We sincerely thank the Digaale community who participated in this study, as well as Hamse Shaban Ahmed, Ayaan Ismail Adan, Khadar Abiib Ahmed, Ayaan Mohamoud Ali, Hamda Awil Garaad, Ahmed Yusuf Mohamed, Suaad Abdi Osman, Amiin Abdi Ismail, Nimco Abdilahi Ismail, AbdiFatah Mohamed Ahmed, Mustafe Shugri Mohamed, and Nimco Mohamed Abdi from the Republic of Somaliland Ministry of Health Development for their data collection efforts. Electronic data solutions were provided by LSHTM Open Data Kit (odk.lshtm.ac.uk)

Reference list

1. United Nations High Commissioner for Refugees. UNHCR - Refugee Statistics [Internet]. [cited 2023 Mar 2]. Available from: <https://www.unhcr.org/refugee-statistics/>
2. van Zandvoort K, Checchi F, Diggle E, Eggo RM, Gadroen K, Mulholland K, et al. Pneumococcal conjugate vaccine use during humanitarian crises. *Vaccine*. 2019 23;37(45):6787–92.
3. Heudtlass P, Speybroeck N, Guha-Sapir D. Excess mortality in refugees, internally displaced persons and resident populations in complex humanitarian emergencies (1998–2012) – insights from operational data. *Conflict and Health*. 2016 Jul 20;10(1):15.
4. Bellos A, Mulholland K, O'Brien KL, Qazi SA, Gayer M, Checchi F. The burden of acute respiratory infections in crisis-affected populations: a systematic review. *Conflict and Health*. 2010;4(1):3.
5. O'Brien KL, Baggett HC, Brooks WA, Feikin DR, Hammitt LL, Higdon MM, et al. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. *The Lancet*. 2019 Aug 31;394(10200):757–79.
6. Kohrt BA, Mistry AS, Anand N, Beecroft B, Nuwayhid I. Health research in humanitarian crises: an urgent global imperative. *BMJ Global Health*. 2019 Nov 1;4(6):e001870.
7. Turner P, Turner C, Jankhot A, Helen N, Lee SJ, Day NP, et al. A Longitudinal Study of *Streptococcus pneumoniae* Carriage in a Cohort of Infants and Their Mothers on the Thailand-Myanmar Border. *PLOS ONE*. 2012 May 31;7(5):e38271.
8. WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control) [Internet]. 2019 [cited 2023 Mar 2]. Prequalified vaccines. Available from: <https://extranet.who.int/pqweb/vaccines/prequalified-vaccines>
9. Pfizer. U.S. FDA Approves PREVNAR 20™, Pfizer's Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older | Pfizer [Internet]. 2021 [cited 2021 Sep 14]. Available from: <https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-prevnar-20tm-pfizers-pneumococcal-20-valent>
10. Merck. Merck.com. 2021 [cited 2021 Sep 14]. Merck Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes. Available from: <https://www.merck.com/news/merck-announces-u-s-fda-approval-of-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-adults-18-years-and-older-caused-by-15-serot/>
11. Bogaert D, De Groot R, Hermans PWM. *Streptococcus pneumoniae* colonisation: the key to pneumococcal disease. *Lancet Infect Dis*. 2004 Mar;4(3):144–54.
12. van Zandvoort K, Bobe MO, Hassan AI, Abdi MI, Ahmed MS, Soleman SM, et al. Social contacts and other risk factors for respiratory infections among internally displaced people in Somaliland. *Epidemics*. 2022 Dec 1;41:100625.
13. FLOQSwabs | COPAN Diagnostics Inc. [Internet]. [cited 2023 Mar 2]. Available from: <https://www.copanusa.com/sample-collection-transport-processing/floqswabs/>
14. Satzke C, Turner P, Virolainen-Julkunen A, Adrian PV, Antonio M, Hare KM, et al. Standard method for detecting upper respiratory carriage of *Streptococcus pneumoniae*: Updated recommendations from the World Health Organization Pneumococcal Carriage Working Group. *Vaccine*. 2013 Dec;32(1):165–79.

15. Pell CL, Ortika BD, Van Zandvoort K, Wee-Hee A, Mulholland EK, Checchi F, et al. Effect of transport conditions on recovery of *Streptococcus pneumoniae*. Abstract presented at: The 12th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); 2022 Jun; Toronto, Canada.
16. THERMOCON CLASSIC 15.5 - THERMOCON [Internet]. [cited 2023 Mar 2]. Available from: <https://thermocon-coldchain.com/en/produkt/thermocon-classic-15-5/>
17. Dunne EM, Murad C, Sudigdoadi S, Fadlyana E, Tarigan R, Indriyani SAK, et al. Carriage of *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Moraxella catarrhalis*, and *Staphylococcus aureus* in Indonesian children: A cross-sectional study. PLOS ONE. 2018 Apr 12;13(4):e0195098.
18. Satzke C, Dunne EM, Choummanivong M, Ortika BD, Neal EFG, Pell CL, et al. Pneumococcal carriage in vaccine-eligible children and unvaccinated infants in Lao PDR two years following the introduction of the 13-valent pneumococcal conjugate vaccine. Vaccine. 2019 Jan 7;37(2):296–305.
19. Carvalho M da GS, Tondella ML, McCaustland K, Weidlich L, McGee L, Mayer LW, et al. Evaluation and Improvement of Real-Time PCR Assays Targeting *lytA*, *ply*, and *psaA* Genes for Detection of Pneumococcal DNA. Journal of Clinical Microbiology. 2007 Aug;45(8):2460–6.
20. Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants - No Study Results Posted - ClinicalTrials.gov [Internet]. [cited 2019 Jun 24]. Available from: <https://clinicaltrials.gov/ct2/show/results/NCT03197376>
21. Lumley T. Complex Surveys: A Guide to Analysis Using R. John Wiley & Sons; 2011. 292 p.
22. Lumley T. survey: analysis of complex survey samples. 2020.
23. Løchen A, Truscott JE, Croucher NJ. Analysing pneumococcal invasiveness using Bayesian models of pathogen progression rates. PLoS Comput Biol. 2022 Feb;18(2):e1009389.
24. Qian G, Toizumi M, Clifford S, Le LT, Papastilianou T, Satzke C, et al. Association of pneumococcal carriage in infants with the risk of carriage among their contacts in Nha Trang, Vietnam: A nested cross-sectional survey. PLoS Med. 2022 May;19(5):e1004016.
25. Neal EFG, Chan J, Nguyen CD, Russell FM. Factors associated with pneumococcal nasopharyngeal carriage: A systematic review. PLOS Glob Public Health. 2022;2(4):e0000327.
26. le Polain de Waroux O, Flasche S, Kucharski AJ, Langendorf C, Ndazima D, Mwangi-Amumpaire J, et al. Identifying human encounters that shape the transmission of *Streptococcus pneumoniae* and other acute respiratory infections. Epidemics. 2018 Dec;25:72–9.
27. Neal EFG, Flasche S, Nguyen CD, Ratu FT, Dunne EM, Koyamaibole L, et al. Associations between ethnicity, social contact, and pneumococcal carriage three years post-PCV10 in Fiji. Vaccine. 2020 Jan 10;38(2):202–11.
28. Hill PC, Akisanya A, Sankareh K, Cheung YB, Saaka M, Lahai G, et al. Nasopharyngeal Carriage of *Streptococcus pneumoniae* in Gambian Villagers. Clin Infect Dis. 2006 Sep 15;43(6):673–9.
29. Nackers F, Cohuet S, le Polain de Waroux O, Langendorf C, Nyehangane D, Ndazima D, et al. Carriage prevalence and serotype distribution of *Streptococcus pneumoniae* prior to 10-valent pneumococcal vaccine introduction: A population-based cross-sectional study in South Western Uganda, 2014. Vaccine. 2017 18;35(39):5271–7.
30. Hammit LL, Akech DO, Morpeth SC, Karani A, Kihuha N, Nyongesa S, et al. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of *Streptococcus pneumoniae* and non-typeable *Haemophilus influenzae* in Kilifi, Kenya: findings from cross-sectional carriage studies. The Lancet Global Health. 2014 Jul 1;2(7):e397–405.

31. Heinsbroek E, Tafatatha T, Phiri A, Swarhout TD, Alaerts M, Crampin AC, et al. Pneumococcal carriage in households in Karonga District, Malawi, before and after introduction of 13-valent pneumococcal conjugate vaccination. *Vaccine*. 2018 Nov 19;36(48):7369–76.
32. Clifford S, Knoll MD, O'Brien KL, Pollington TM, Moodley R, Prieto-Merino D, et al. Global landscape of *Streptococcus pneumoniae* serotypes colonising healthy individuals worldwide before vaccine introduction; a systematic review and meta-analysis [Internet]. medRxiv; 2023 [cited 2023 Aug 28]. p. 2023.03.09.23287027. Available from: <https://www.medrxiv.org/content/10.1101/2023.03.09.23287027v1>
33. Cohen R, Cohen JF, Chalumeau M, Levy C. Impact of pneumococcal conjugate vaccines for children in high- and non-high-income countries. *Expert Review of Vaccines*. 2017 Jun 3;16(6):625–40.
34. Flasche S, Hoek AJV, Sheasby E, Waight P, Andrews N, Sheppard C, et al. Effect of Pneumococcal Conjugate Vaccination on Serotype-Specific Carriage and Invasive Disease in England: A Cross-Sectional Study. *PLOS Medicine*. 2011 Apr 5;8(4):e1001017.
35. Troeger C, Blacker B, Khalil IA, Rao PC, Cao J, Zimsen SRM, et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet Infectious Diseases*. 2018 Nov 1;18(11):1191–210.
36. Murad C, Dunne EM, Sudigdoadi S, Fadlyana E, Tarigan R, Pell CL, et al. Pneumococcal carriage, density, and co-colonization dynamics: A longitudinal study in Indonesian infants. *Int J Infect Dis*. 2019 Jun 25;86:73–81.
37. Abdullahi O, Karani A, Tigoi CC, Mugo D, Kungu S, Wanjiru E, et al. The prevalence and risk factors for pneumococcal colonization of the nasopharynx among children in Kilifi District, Kenya. *PLoS One*. 2012;7(2):e30787.
38. Lupien A, Gingras H, Bergeron MG, Leprohon P, Ouellette M. Multiple mutations and increased RNA expression in tetracycline-resistant *Streptococcus pneumoniae* as determined by genome-wide DNA and mRNA sequencing. *Journal of Antimicrobial Chemotherapy*. 2015 Jul 1;70(7):1946–59.
39. Ousmane S, Diallo BA, Ouedraogo R. Genetic Determinants of Tetracycline Resistance in Clinical *Streptococcus pneumoniae* Serotype 1 Isolates from Niger. *Antibiotics*. 2018 Mar;7(1):19.
40. Okitsu N, Kaieda S, Yano H, Nakano R, Hosaka Y, Okamoto R, et al. Characterization of *ermB* Gene Transposition by *Tn1545* and *Tn917* in Macrolide-Resistant *Streptococcus pneumoniae* Isolates. *J Clin Microbiol*. 2005 Jan;43(1):168–73.
41. Rolfe RJ, Shaikh H, Tillekeratne LG. Mass drug administration of antibacterials: weighing the evidence regarding benefits and risks. *Infectious Diseases of Poverty*. 2022 Jun 30;11(1):77.
42. Rodrigues F, Foster D, Nicoli E, Trotter C, Vipond B, Muir P, et al. Relationships between rhinitis symptoms, respiratory viral infections and nasopharyngeal colonization with *Streptococcus pneumoniae*, *Haemophilus influenzae* and *Staphylococcus aureus* in children attending daycare. *Pediatr Infect Dis J*. 2013 Mar;32(3):227–32.
43. Bojang A, Jafali J, Egere UE, Hill PC, Antonio M, Jeffries D, et al. Seasonality of Pneumococcal Nasopharyngeal Carriage in Rural Gambia Determined within the Context of a Cluster Randomized Pneumococcal Vaccine Trial. *PLOS ONE*. 2015 Jul 1;10(7):e0129649.